Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents
F Poordad, D Dieterich - Journal of viral hepatitis, 2012 - Wiley Online Library
During the late 1990s and early 2000s, major advances were made in the treatment of
patients with chronic hepatitis C virus (HCV) infection. Interferon, combination interferon plus …
patients with chronic hepatitis C virus (HCV) infection. Interferon, combination interferon plus …
Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression
Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections can lead to cirrhosis, end-
stage liver disease, and hepatocellular carcinoma. Over the past decade, studies of …
stage liver disease, and hepatocellular carcinoma. Over the past decade, studies of …
genetic factors that modify the outcome of viral hepatitis
AF Stättermayer, T Scherzer… - Alimentary …, 2014 - Wiley Online Library
Background Genetic factors can play an important role for treatment response and disease
progression in chronic viral hepatitis. Aim To review the influence of host genetic factors on …
progression in chronic viral hepatitis. Aim To review the influence of host genetic factors on …
[HTML][HTML] Viral and host factors associated with outcomes of hepatitis C virus infection
Z Yan, Y Wang - Molecular medicine reports, 2017 - spandidos-publications.com
Hepatitis C virus (HCV) infection is a major health issue globally. Owing to the progress
made in host genetics and HCV molecular virology, emerging data have suggested that the …
made in host genetics and HCV molecular virology, emerging data have suggested that the …
TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects
R Steponaitiene, J Kupcinskas, S Survilaite… - Advances in medical …, 2016 - Elsevier
Purpose Inter-individual thiopurine metabolism variability can influence treatment outcomes
in inflammatory bowel disease (IBD) patients. Genetic polymorphisms in thiopurine …
in inflammatory bowel disease (IBD) patients. Genetic polymorphisms in thiopurine …
[PDF][PDF] Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3
K Rembeck, J Waldenström, K Hellstrand… - …, 2014 - Wiley Online Library
The present study evaluated the impact of variations in the inosine triphosphate
pyrophosphatase (ITPase) gene (ITPA) on treatment outcome in patients with hepatitis C …
pyrophosphatase (ITPase) gene (ITPA) on treatment outcome in patients with hepatitis C …
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy
Anaemia frequently complicates peginterferon/ribavirin therapy for chronic hepatitis C
infection. Better prediction of anaemia, ribavirin dose reduction or erythropoietin (EPO) …
infection. Better prediction of anaemia, ribavirin dose reduction or erythropoietin (EPO) …
The role of viral and host genetics in natural history and treatment of chronic HCV infection
JS Doyle, ME Hellard, AJ Thompson - Best Practice & Research Clinical …, 2012 - Elsevier
Understanding of the natural history and treatment responsiveness of chronic hepatitis C
virus (HCV) infection has evolved rapidly in recent years. Advances in HCV molecular …
virus (HCV) infection has evolved rapidly in recent years. Advances in HCV molecular …
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment
A D'Avolio, A Ciancio, M Siccardi… - Therapeutic drug …, 2012 - journals.lww.com
Background Functional variants of inosine triphosphatase (ITPA) were recently found to
protect against ribavirin (RBV)-induced hemolytic anemia. However, no definitive data are …
protect against ribavirin (RBV)-induced hemolytic anemia. However, no definitive data are …
[HTML][HTML] Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals
N Coppola, M Pisaturo, R Zampino… - World Journal of …, 2015 - ncbi.nlm.nih.gov
About 130-170 million people are infected with the hepatitis C virus (HCV) worldwide and
more than 350000 people die each year of HCV-related liver diseases. The combination of …
more than 350000 people die each year of HCV-related liver diseases. The combination of …